Advanced Gastric Cancer Clinical Trial
Official title:
A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer
It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the growth of tumors like renal cell carcinoma.However, RAD001 alone looks not enough to control gastric cancer. By the mechanisms above, RAD001 can show additive or synergistic effect in combination with conventional chemotherapy. In this study, XELOX was selected as a conventional combination chemotherapy because it was proven very active and safe in gastric cancer. Combination of XELOX and RAD001 has been never tried for the treatment of cancer patients yet. So, the optimal dose will be first determined in this phase I study
For the first cohort of this phase I study, each drug of capecitabine, oxaliplatin, and RAD001 will be started at one or two dose below the ordinary full dose of each drug as a single agent. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Completed |
NCT00821990 -
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
|
Phase 3 | |
| Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
| Completed |
NCT01248403 -
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
|
Phase 3 | |
| Not yet recruiting |
NCT01206218 -
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00976768 -
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
|
Phase 2 | |
| Completed |
NCT01851941 -
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03223376 -
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
|
Phase 3 | |
| Completed |
NCT03609359 -
Lenvatinib and Pembrolizumab Simultaneous Combination Study
|
Phase 2 | |
| Completed |
NCT03350477 -
Bioinformation Therapy for Gastric Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT02935634 -
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03579784 -
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
|
Phase 2 | |
| Completed |
NCT02952729 -
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
|
Phase 1 | |
| Recruiting |
NCT02072317 -
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
|
Phase 2 | |
| Terminated |
NCT01402401 -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
|
Phase 2 | |
| Completed |
NCT01503372 -
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT01472250 -
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|
N/A | |
| Recruiting |
NCT01015339 -
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 3 | |
| Completed |
NCT00842491 -
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT01238055 -
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
|
Phase 2 |